Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Ashley D Hadjis, Griffin W White, Christopher Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Andrew H Matthews, Mary Ellen Martin, Daria V Babushok, Alexander Perl, David L. Porter, Alison W Loren, Keith W Pratz, Selina M Luger, Shannon R McCurdy

Blood (2023) 142 (Supplement 1): 376.

https://doi.org/10.1182/blood-2023-188978

Published: 2023

Journal Articles

Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life (HRQoL) Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN (EA) E2906 Phase 3 Trial

Blood (2023) 142 (Supplement 1): 594.

https://doi.org/10.1182/blood-2023-189734

Published: 2023

Journal Articles

Patient-Reported Outcome Measures Associated with Overall Survival and Acute Care Use in Patients with Newly Diagnosed Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Acute Lymphoblastic Leukemia

Seiichi Villalona, Xin Wang, Peter Gabriel, Abigail Doucette, Shannon R McCurdy, Alexander Perl, Selina M Luger, Noelle V. Frey, Ximena Jordan Bruno, Elizabeth O Hexner, Daria V Babushok, David L. Porter, Alison W Loren, Keith W Pratz, Catherine Lai

Blood (2023) 142 (Supplement 1): 5183.

https://doi.org/10.1182/blood-2023-178247

Published: 2023

Journal Articles

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Blood (2023) 142 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2023-189648

Published: 2023

Journal Articles

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Blood (2023) 142 (Supplement 1): 955.

https://doi.org/10.1182/blood-2023-180185

Published: 2023

Journal Articles

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

Matthew P Connor, Neeharika Prathapa, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander Perl, David L. Porter, Arlene Zeringue, Joseph H. Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok

Blood (2023) 142 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2023-179383

Published: 2023

Journal Articles

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Blood (2023) 142 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2023-186978

Published: 2023

Journal Articles

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Blood (2022) 140 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2022-171751

Published: 2022

Journal Articles

ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Recher, Andre C. Schuh, Sunil Babu, Monique Dail, Grace Ku, Yan Sun, Jalaja Potluri, Brenda Chyla, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 1441–1444.

https://doi.org/10.1182/blood-2022-169509

Published: 2022

Journal Articles

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1022–1024.

https://doi.org/10.1182/blood-2022-168036

Published: 2022

Journal Articles

Fried's Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Cristian C. Taborda, Shannon H Gier, Avery W Stivale, Alexander E. Perl, Saar Gill, Daria V. Babushok, Elizabeth O. Hexner, Noelle V. Frey, Catherine Lai, Ximena Jordan Bruno, Mary Ellen Martin, Ivan Maillard, David L. Porter, Alison W. Loren, Keith W. Pratz, Selina M. Luger, Phyllis A. Gimotty, Shannon R. McCurdy

Blood (2022) 140 (Supplement 1): 10825–10827.

https://doi.org/10.1182/blood-2022-169924

Published: 2022

Journal Articles

Patient-Reported Outcome Measures in Newly Diagnosed Acute Myeloid Leukemia: An Exploratory Analysis of Real-World Data

Xin Wang, Peter Gabriel, Abigail Doucette, Phyllis A. Gimotty, Kelly D. Getz, Samuel Takvorian, Alexander E. Perl, Shannon R. McCurdy, Selina M. Luger, Noelle V. Frey, Alison W. Loren, Elizabeth O. Hexner, Daria V. Babushok, David L. Porter, Keith W. Pratz, Catherine Lai

Blood (2022) 140 (Supplement 1): 13287–13288.

https://doi.org/10.1182/blood-2022-170733

Published: 2022

Journal Articles

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Keith W. Pratz, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Jun-Ho Jang, Su-Peng Yeh, Grace Ku, Ying Zhou, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 529–531.

https://doi.org/10.1182/blood-2022-158518

Published: 2022

Journal Articles

A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma

Blood (2021) 138 (Supplement 1): 4401.

https://doi.org/10.1182/blood-2021-149329

Published: 2021

Journal Articles

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Blood (2021) 138 (Supplement 1): 469.

https://doi.org/10.1182/blood-2021-153955

Published: 2021

Journal Articles

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

Janna C. Minehart, Christopher Catania, Linda Perry, Mary Ellen Martin, Jacqueline Smith, Shannon R. McCurdy, Keith W. Pratz, Selina M. Luger, Colleen Timlin, Alexander E. Perl, Mindy Schuster, David L Porter, Alison W. Loren, Elizabeth O. Hexner, Noelle V Frey

Blood (2021) 138 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2021-153920

Published: 2021

Journal Articles

Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia

Andrew Matthews, Alexander E. Perl, Selina M. Luger, Daria V. Babushok, Noelle V Frey, Saar Gill, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, David L. Porter, Edward A. Stadtmauer, Alison W. Loren, Vikram R Paralkar, Ivan Maillard, David Margolis, Keith W. Pratz

Blood (2021) 138 (Supplement 1): 795.

https://doi.org/10.1182/blood-2021-149158

Published: 2021

Journal Articles

Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective

Keith W. Pratz, Xinglei Chai, Jipan Xie, Lei Yin, Xiaoyu Nie, Melissa Montez, Erica Iantuono, Lisa Downs, Esprit Ma

Blood (2021) 138 (Supplement 1): 112.

https://doi.org/10.1182/blood-2021-148338

Published: 2021

Journal Articles

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod A. Pullarkat, Brian A. Jonas, Christian Recher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo

Blood (2021) 138 (Supplement 1): 224.

https://doi.org/10.1182/blood-2021-145639

Published: 2021

NARROW

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life (HRQoL) Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN (EA) E2906 Phase 3 Trial

Patient-Reported Outcome Measures Associated with Overall Survival and Acute Care Use in Patients with Newly Diagnosed Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Acute Lymphoblastic Leukemia

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Fried's Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Patient-Reported Outcome Measures in Newly Diagnosed Acute Myeloid Leukemia: An Exploratory Analysis of Real-World Data

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia

Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only